

SAMPLE CODING

Pediatric Non-Hodgkin's Lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL)

TYPE	CODE		DESCRIPTION
Diagnosis: ICD-10-CM	C83.30-C83.38		Diffuse large B-cell lymphoma, lymph nodes of various sites
	C83.398		Diffuse large B-cell lymphoma of other extranodal and solid organ sites
	C83.70-C83.79		Burkitt lymphoma, various sites
	C91.A0		Mature B-cell leukemia Burkitt-type not having achieved remission
Drug: HCPCS	J9312		Injection, rituximab, 10 mg
HCPCS: Modifier*	JW		Drug amount discarded/not administered to any patient
	JZ		Zero drug amount discarded/not administered to any patient
Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	10-digit	11-digit	
	50242-051-21	50242-0051-21	100 mg/10 mL single-dose vial
	50242-053-06	50242-0053-06	500 mg/50 mL single-dose vial
Administration procedures: CPT	96413		Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415		Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
	96417		Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Biogen do not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Rituxan® is a registered trademark of Biogen.

Please see the full Prescribing Information, including Boxed WARNINGS and Medication Guide, for Important Safety Information.



^{*}The JW modifier is required on claims for all single-dose container or single-use drugs when an amount is discarded. The JZ modifier is required to be used as of July 1, 2023. For more information on the JW and JZ modifiers, visit CMS.gov.